Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05145491

Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM

Randomized Trial Comparing Immediate Versus Deferred Surgery for Symptomatic Epiretinal Membranes

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
400 (estimated)
Sponsor
Jaeb Center for Health Research · Academic / Other
Sex
All
Age
50 Years
Healthy volunteers
Not accepted

Summary

Vitrectomy to remove an epiretinal membrane (ERM) is one of the most common procedures performed by retinal surgeons. Patients who present with significant macular changes on optical coherence tomography (OCT) but relatively good vision are often advised to defer surgery until vision declines to 20/40 or worse. However, it is unknown if delaying surgery, which allows the foveal architecture to remain compromised and potentially to deteriorate, results in worse visual acuity outcomes than if surgery is performed earlier. In addition, there is a need to better understand predictors of outcomes when surgery is performed and predictors of progression when surgery is deferred. Finally, one of the most common presenting symptoms from an ERM is distortion or metamorphopsia. There are several objective measures of metamorphopsia but none have ever been employed to evaluate ERMs in a randomized clinical trial (RCT) and their usefulness is unknown. The purposes of this study are to better understand the optimal timing of surgery to produce the best visual result, to better understand predictors of outcomes in those who undergo surgery and predictors of progression in those whose are observed, and to better characterize and evaluate the usefulness of metamorphopsia and reading speed measures.

Conditions

Interventions

TypeNameDescription
PROCEDUREImmediate VitrectomySurgery to remove epiretinal membrane (ERM). Vitrectomy will be performed on eyes within 1 month of randomization
PROCEDUREDeferred VitrectomyVitrectomy may be performed only if at least one of the following criteria is met: 1. Decrease in visual acuity ≥10 letters from baseline at a single visit presumed to be from ERM 2. Decrease in visual acuity ≥5 letters from baseline at two consecutive visits presumed to be from ERM a. Visits must be at least one month apart 3. Participant actively requests surgery due to worsening symptoms 4. Complication requires prompt surgical intervention (e.g., macular hole, retinal detachment, non-clearing vitreous hemorrhage)

Timeline

Start date
2022-02-22
Primary completion
2026-12-31
Completion
2026-12-31
First posted
2021-12-06
Last updated
2026-01-28

Locations

46 sites across 2 countries: United States, United Kingdom

Source: ClinicalTrials.gov record NCT05145491. Inclusion in this directory is not an endorsement.